ReviewNature reviews. Rheumatology2022
Assessment of disease outcome measures in systemic sclerosis.
Review in Nature reviews. Rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Understanding patient-reported disease burden in systemic sclerosis: key clinical and demographic features revealed by the EULAR Systemic Sclerosis Impact of Disease (ScleroID) Questionnaire.EULAR rheumatology open · 2026Article
- Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis care & research · 2026Article
- Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.Pharmaceutics · 2026Review
- Impact of male sex in clinical and laboratory features of systemic sclerosis.Advances in rheumatology (London, England) · 2026Article
- IL-32 as a potential biomarker and therapeutic target in cardiovascular disease.Frontiers in immunology · 2026Review
- 'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Structured light imaging mesoscopy: application to skin changes in scleroderma.Biophotonics discovery · 2025Article
- Article
- Low-Carbon Monoxide Diffusing Capacity, Patient-Reported Measures and Reduced Nailfold Capillary Density Are Associated with Interstitial Lung Disease in Systemic Sclerosis.Journal of personalized medicine · 2024Article
- Immune profiling analysis of double-negative T cells in patients with systemic sclerosis.Clinical rheumatology · 2024Article
- Development and validation of a new diagnostic prediction model of ENHO and NOX4 for early diagnosis of systemic sclerosis.Frontiers in immunology · 2024Article
- The role of immunosuppressive myofibroblasts in the aging process and age-related diseases.Journal of molecular medicine (Berlin, Germany) · 2023Review
- Biomarkers in Systemic Sclerosis: An Overview.Current issues in molecular biology · 2023Review
- Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.Nature communications · 2023Article
- Low cognitive functioning and depressive symptoms in patients with rheumatoid arthritis and systemic sclerosis: a clinical study.BMC psychiatry · 2023Article
- Article
- Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.Journal of inflammation research · 2023Review
- Malignancies in systemic rheumatic diseases: A mini review.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The assessment of disease activity in systemic sclerosis (SSc) is challenging owing to its heterogeneous manifestations across multiple organ systems, the variable rate of disease progression and regression, and the relative paucity of patients in early-phase therapeutic trials. Despite some recent successes, most clinical trials have failed to show efficacy, underscoring the need for improved outcome measures linked directly to disease pathogenesis, particularly applicable for biomarker studies focused on skin disease. Current outcome measures in SSc-associated interstitial lung disease and SSc skin disease are largely adequate, although advancing imaging technology and the incorporation of skin mRNA biomarkers might provide opportunities for earlier detection of the therapeutic effect. Biomarkers can further inform pathogenesis, enabling early phase trials to act as reverse translational studies through the incorporation of routine high-throughput sequencing.
Indexed as
Identifiers
35859133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.